The influence of centralized volume-based procurement on the use of insulin
Objective To analyze the implementation of special insulin policy before and after one year,and to evaluate its impact on clinical use of insulin.Methods The data of one year before(May 20,2021～May 19,2022)and one year after(May 20,2022～May 19,2023)centralized procurement(insulin special)in a hospital were analyzed,and the unit price and quantity of insulin of different manufacturers and specifications were compared before and after the implementation.The defined daily dose(DDD)method was used to calculate the DDDs,the defined daily cost(DDC),the actual cost saving and the progress of collection.Results The number of insulin varieties increased from 19 to 26 after procurement.After procurement,the price of all insulin drugs decreased to different degrees,and the price decreased by more than 30%,with an average decrease of 46.61%.After procurement,the sales volume of all varieties increased,and the average sales volume increased by 82.08%.The top two drugs in the ranking of DDDs before and after procurement were insulin aspartate 30 injection(Novo Nordisk pen refill)and insulin aspartate injection(Novo Nordisk pen refill).After procurement,the total cost savings of all insulin drug varieties was 1 417 694.52 yuan,with an average savings of 78 760.81 yuan.Conclusion After the implementation of centralized volume-based procurement,insulin sales increased,drug prices decreased and cost savings were obvious,which alleviated the financial burden of diabetic patients and the pressure of medical insurance.
万方数据
维普
